Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-throughput microarray technologies: from genomics to clinics.

L Bubendorf1

  • 1Institute for Pathology, University of Basel, Switzerland. lbubendo@bluewin.ch

European Urology
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025
Same author

Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Unravelling lung adenocarcinoma with mucinous histology and its translational implications.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023
Same author

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future.

ESMO open·2021
Same author

Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.

Cancer immunology, immunotherapy : CII·2020
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
Same journal

Re: Hormone Therapy Use and Duration with Postoperative Radiotherapy for Recurrent Prostate Cancer: an Individual Patient Data Meta-analysis.

European urology·2026
Same journal

Re: Nguyen DD, Tadayon Najafabadi B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026
Same journal

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

European urology·2026
Same journal

Re: Fecal Microbiota Transplantation plus Immunotherapy in Metastatic Renal Cell Carcinoma: The Phase 1 PERFORM Trial.

European urology·2026
See all related articles

New microarray technologies enable the simultaneous analysis of thousands of genes, accelerating the discovery and validation of novel cancer targets. These advancements promise to improve diagnostics and treatments for urologic tumors.

Area of Science:

  • Genomics
  • Molecular Biology
  • Oncology

Background:

  • Effective treatments for advanced cancers like kidney and prostate cancer remain limited.
  • Understanding cancer's molecular mechanisms is crucial for developing new diagnostics and therapies.
  • Genomic advancements, including human genome sequencing, provide a foundation for disease research.

Purpose of the Study:

  • To introduce and highlight the utility of DNA microarrays and tissue microarrays (TMAs) in cancer research.
  • To demonstrate how these technologies can accelerate the identification and validation of new diagnostic and therapeutic targets in urologic tumors.

Main Methods:

  • Utilizing DNA microarrays for simultaneous analysis of thousands of gene mRNA expressions.
  • Developing and employing tissue microarrays (TMAs) for high-throughput in situ analysis of genetic alterations (DNA, RNA, protein) in numerous tumor specimens.

Related Experiment Videos

  • Applying in situ hybridization and immunohistochemistry on TMAs for large-scale validation.

    • Main Results:

    • DNA microarrays facilitate comprehensive gene expression surveys, identifying novel genes and pathways in cancer development.
    • Tissue microarrays (TMAs) enable efficient validation of candidate genes' clinical relevance across large tumor series.
    • These technologies allow for massively parallel analysis on DNA, RNA, and protein levels.

    Conclusions:

    • DNA microarrays and TMAs offer a powerful combined approach for discovering and validating cancer-related genes.
    • These technologies are poised to significantly advance the molecular understanding of urologic tumors.
    • The findings will accelerate the identification of new prognostic markers and therapeutic targets for urologic cancers.